Sun Pharma Roars Back To Growth Path After Sluggish Growth.

In the past five years, Sun Pharma has undergone a significant transformation. Despite the challenges, including the Ranbaxy acquisition in 2014 which initially impacted profits, founder Dilip Shanghvi implemented a renewed strategy focused on boosting the specialty drugs business and expanding the portfolio through mergers and acquisitions. This resulted in an impressive turnaround, with the company achieving its highest-ever consolidated revenue of Rs 43,279 crore in FY2023.